Bevacizumab
Author:
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference13 articles.
1. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2. Transplacental Carcinogenesis by Stilbestrol
3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
4. Cancer burden in the year 2000. The global picture
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs;International Journal of Nanomedicine;2024-07
2. Validation of an enzyme-linked immunosorbent assay test-system for bevacizumab concentration determing in biological fluids;Drug development & registration;2024-04-26
3. Peptides for therapeutic applications – challenges and chances;Pure and Applied Chemistry;2024-01-01
4. The role of endothelial cell–pericyte interactions in vascularization and diseases;Journal of Advanced Research;2024-01
5. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma;Frontiers in Immunology;2023-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3